A new class of diabetes medication

October 18, 2006

Can it be hope for Merck? The selling point is no weight gain. Trials show a decrease of 0.77 in A1c over 12 weeks.



Related posts:

  1. Prescription medication pay for performance, and the rationale behind it
  2. AstraZeneca’s weight gain and diabetes side effect cover up, and the sleazy Seroquel sex scandal
  3. Migraines and the stigma of chronic pain medication use
  4. Varicella vaccine: Did Merck pull a fast one?
  5. Surgery for type 2 diabetes?
  6. A new class of antibiotic?
  7. Should Singulair be sold over the counter?


KevinMD.com on Facebook


  Follow on Twitter   Subscribe



Tagged as: diabetes

{ 1 comment }

1 Esquivel October 18, 2006 at 11:37 am

I’m sure CJD already has his first case written up, and he’s out there hunting for someone’s name to throw on the lawsuit already. :-)

Comments on this entry are closed.

Previous post: "Waste of a mind": Why medical students shun geriatrics

Next post: The inability to take no for an answer

Site Meter